Loading…
* Free cash flow = OCF − net investing outflow (the filings carry no standalone capex line).
Dividends declared (per SOCE filings): FY2022 10,500 · FY2023 8,500 · FY2024 0 — 3-yr total 19,000
Operates in Pharma — Distribution. Per the activity note to the FY2024 annual report, the company buys and sells pharmaceutical medications.
| Line item | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | CAGR |
|---|---|---|---|---|---|---|---|---|---|
| 13,583 | 13,448 | 17,017 | 19,178 | 22,454 | 23,375 | 29,747 | 36,571 | +15.2% | |
| 6,904 | 6,939 | 7,393 | 7,302 | 7,194 | 8,487 | 8,620 | 13,485 | +10.0% | |
| TOTAL ASSETS | 20,487 | 20,387 | 24,410 | 26,481 | 29,648 | 31,862 | 38,366 | 50,056 | +13.6% |
| 7,762 | 6,371 | 4,745 | 6,161 | 5,152 | 8,288 | 8,764 | 7,897 | +0.2% | |
| Total Non-Current Liabilities | 2,513 | 1,848 | 2,081 | 2,096 | 1,160 | 665 | 662 | 4,354 | +8.2% |
| TOTAL LIABILITIES | 10,276 | 8,219 | 6,825 | 8,257 | 6,312 | 8,953 | 9,426 | 12,251 | +2.5% |
| 10,211 | 12,168 | 17,585 | 18,223 | 23,336 | 22,908 | 28,940 | 37,806 | +20.6% | |
| Balance Check (Assets - L&E) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| Debt analysis | |||||||||
| Total Debt | 5,847 | 2,019 | 3,001 | 3,169 | 2,801 | 1,440 | 1,092 | 5,228 | -1.6% |
| Cash & Equivalents | 106 | 1,329 | 1,890 | 1,187 | 1,021 | 2,041 | 2,794 | 1,470 | +45.5% |
| Net Debt | 5,740 | 690 | 1,111 | 1,982 | 1,780 | 601 | 1,701 | 3,758 | -5.9% |
Shareholders, directors and group links from the companyinfo.ge public register — as filed, so stakes need not sum to 100% where a holding is undisclosed.
Ownership & directors from companyinfo.ge (public corporate registry).
Ranked by how close each latest revenue is to this one — not a curated comp set. Open this set in Compare →